ERBB2 and neoplasm: showed more diffuse pS10 Histone H3 (pharmacodynamic marker of mitotic arrest) that was not restricted to HER2-positive tumor regions when treated with Trastuzumab-MMAE (bystander payload) compared to Trastuzumab-MMAF (nonbystander payload) [36].